Project Details
Description
Studies in my laboratory are directed to gain a better understanding of antigen receptor gene
assembly, also known as V(D)J recombination, a reaction that is central for the generation of a
normal and diverse immune system. Antigen receptor gene assembly is directed by consensus
DNA sequences and the complete reaction can be divided in recognition and cleavage of the
DNA followed by processing and joining of the cleaved DNA ends. The early steps of
recognition and cleavage of the DNA sequences are mediated by the products of the
recombination activating genes 1 and 2 (RAG1 and RAG2). Inactivation of these genes in
either human or mouse results in a severe combined immunodeficiency. Despite rapid
progress in understanding the early steps of V(D)J recombination, the molecular mechanisms
that govern regulated cleavage, the focus of study in this proposal, processing and joining of
the ends remain largely obscure. So far, only five proteins have been implicated in the joining
process: DNA-PKcs, Ku, XRCC4, ligase IV and Artemis, which are also essential for DNA
double-strand break repair. Moreover, it has been shown that mutations and/or deletions in
human ligase IV and Artemis produce severe immunodeficiencies, genomic instability and
cancer. Mice deficient in DNA-PKcs, Ku, XRCC4, ligase IV and Artemis are severely
immunodeficient and prompt to B-cell leukemias.
V(D)J recombination normally yields products that are mean to produce immunoglobulins and
T cell receptors. However, it has become clear that aberrant recombination events, which occur
at a significant rate, could give rise to translocations. In most cases, these translocations are
the cause of lymphomas and leukemias, some of the most common types of human cancer.
The proposed studies, which focus on the understanding of the molecular mechanism of
regulated cleavage, constitute an important step towards understanding the etiology of major
diseases of the immune system. It is predicted that all the information gained through our
studies will not only increase our understanding of the reaction but it will also open new
strategies for therapeutic information and implementation of prevention and treatment against
diseases of the immune system.
Status | Finished |
---|---|
Effective start/end date | 1/07/04 → 30/06/08 |
Funding
- American Cancer Society: $714,000.00